Cambridge pharmaceutical giant AstraZeneca and Merck & Co have won a US FDA award of Orphan Drug Designation for Lynparza (olaparib) for the treatment of pancreatic cancer. The core IP behind the technology arose from discoveries made by Professor Steve ...